Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 33
GLP-1 Drugs and Psoriasis Healthcare Use
A new JEADV letter examines whether GLP-1 and GLP-1/GIP drugs like tirzepatide and semaglutide change healthcare use in psoriasis patients.
GLP-1 drugs and sleep apnoea: the survey
A pan-European survey across 24 ESADA centres maps how sleep physicians are using GLP-1 receptor agonists for OSA, and where practice remains uncoordinated.
Semaglutide and burn pain: a mouse study
A mouse study found spinal semaglutide injections eased burn-injury pain via an opioid pathway. Here is why that is not evidence it treats pain in humans.
MASLD treatment: what a 2026 review found
A Gut and Liver review maps current MASLD treatment options and a growing pipeline, from lifestyle change to GLP-1 agonists and thyroid receptor drugs.
Oral incretin therapies for weight loss
Oral semaglutide and orforglipron bring GLP-1 based weight management into tablet form. Here is what the evidence does and does not show.
Tesamorelin, tirzepatide, and weight loss
A forum question cannot show whether sermorelin changes tirzepatide-related weight loss. Here is what tesamorelin evidence and labeling say.
Tirzepatide for postbariatric hypoglycemia
A three-patient case report found fewer post-meal low-glucose episodes after tirzepatide, but it cannot establish a treatment recommendation.
The trade-offs of widespread GLP-1 use
GLP-1 medicines have strong trial evidence, but widespread use also raises questions about access, marketing, and evidence beyond the headlines.
GLP-1 injection site reactions explained
Tirzepatide, semaglutide and other GLP-1 drugs cause injection site and skin reactions in about a third of reported adverse events, an FDA data review finds.
GLP-1 skin reactions: what FAERS shows
A 2026 Clinics in Dermatology FAERS review maps injection site reactions, alopecia, urticaria, and rarer skin events in GLP-1 receptor agonist users.
GLP-1 FAERS safety signals explained
A 2026 pharmacovigilance paper examined 243,114 FAERS reports for GLP-1 agents. Tirzepatide led at 133,100. What the signal patterns mean.
GLP-1 Drugs in Children Ages 8-11: Trends
A 3.5-million-child Pediatrics study found GLP-1 prescriptions for 8-to-11-year-olds grew 310-fold from 2019 to 2026, all off-label.